/IMGN
IMGN Stock - ImmunoGen, Inc.
Healthcare|BiotechnologyNASDAQ
$31.23+0.02%
+$0.01 (+0.02%) • Feb 9
48
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.95
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).0
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.73
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-59.3%upside
Target: $12.71
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for IMGN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$30.92 – $31.55
TARGET (TP)$12.72
STOP LOSS$28.74
RISK/REWARD1:-7.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.17
52W High$31.25
52W Low$3.61
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | $108.78M | $69.86M | $132.30M | $82.27M | $53.82M |
| Gross Profit | $108.61M | $69.86M | $17.71M | $-32,251,000 | $-120,070,000 |
| Gross Margin | 99.8% | 100.0% | 13.4% | -39.2% | -223.1% |
| Operating Income | $-220,893,000 | $-125,073,000 | $-135,485,000 | $-92,173,000 | $-160,479,000 |
| Net Income | $-222,929,000 | $-139,303,000 | $-66,683,000 | $-122,093,000 | $-167,873,000 |
| Net Margin | -204.9% | -199.4% | -50.4% | -148.4% | -311.9% |
| EPS | $-0.88 | $-1.08 | $-0.38 | $-0.82 | $-1.20 |
Company Overview
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
50%
Hold / Neutral
2
50%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
2 Bullish2 Neutral/Bearish
Price Targets
$18
Average Target
↓ 43.7% Downside
Now
$8
Low
$18
Average
$31
High
Based on 7 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 1st 2023 | Guggenheim | Downgrade | Neutral | $31← $25 |
| November 20th 2023 | Goldman | Initiation | Neutral | $17 |
| November 9th 2023 | Deutsche Bank | Initiation | Buy | $25 |
| October 6th 2023 | Oppenheimer | Initiation | Perform | $16 |
| May 3rd 2023 | Piper Sandler | Upgrade | Overweight | $16← $6 |
| November 21st 2022 | Truist | Initiation | Buy | $10 |
| September 9th 2022 | Barclays | Initiation | Overweight | $8 |
Earnings History & Surprises
IMGNBeat Rate
76%
Last 17 quarters
Avg Surprise
+32.8%
EPS vs Estimate
Beats / Misses
13/4
Last 12 quarters
Latest EPS
$-0.23
Q1 2024
EPS Surprise History
Q2 22
+52.4%
$-0.10vs$-0.21
Q3 22
-9.1%
$-0.24vs$-0.22
Q4 22
-19.2%
$-0.31vs$-0.26
Q1 23
+20.7%
$-0.23vs$-0.29
Q2 23
+36.0%
$-0.16vs$-0.25
Q3 23
+87.5%
$-0.02vs$-0.16
Q4 23
+124.1%
$0.10vs$0.04
Q1 24
-276.9%
$-0.23vs$0.13
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2024 | Oct 31, 2024 | — | — | — | — |
Q3 2024 | Jul 29, 2024 | — | — | — | — |
Q2 2024 | Apr 26, 2024 | — | — | — | — |
Q1 2024 | Mar 6, 2024 | $0.13 | $-0.23 | -276.9% | ✗ MISS |
Q4 2023 | Nov 2, 2023 | $0.04 | $0.10 | +124.1% | ✓ BEAT |
Q3 2023 | Jul 31, 2023 | $-0.16 | $-0.02 | +87.5% | ✓ BEAT |
Q2 2023 | Apr 28, 2023 | $-0.25 | $-0.16 | +36.0% | ✓ BEAT |
Q1 2023 | Mar 1, 2023 | $-0.29 | $-0.23 | +20.7% | ✓ BEAT |
Q4 2022 | Nov 4, 2022 | $-0.26 | $-0.31 | -19.2% | ✗ MISS |
Q3 2022 | Jul 29, 2022 | $-0.22 | $-0.24 | -9.1% | ✗ MISS |
Q2 2022 | May 6, 2022 | $-0.21 | $-0.10 | +52.4% | ✓ BEAT |
Q1 2022 | Feb 25, 2022 | $-0.18 | $-0.17 | +5.6% | ✓ BEAT |
Q4 2021 | Oct 29, 2021 | $-0.19 | $-0.18 | +5.3% | ✓ BEAT |
Q3 2021 | Jul 30, 2021 | $-0.18 | $-0.15 | +16.7% | ✓ BEAT |
Q2 2021 | May 10, 2021 | $-0.19 | $-0.17 | +10.5% | ✓ BEAT |
Q1 2021 | Feb 12, 2021 | $-0.08 | $0.16 | +300.0% | ✓ BEAT |
Q4 2020 | Nov 6, 2020 | $-0.20 | $-0.13 | +35.0% | ✓ BEAT |
Q3 2020 | Jul 31, 2020 | $-0.18 | $-0.14 | +22.2% | ✓ BEAT |
Q2 2020 | May 1, 2020 | $-0.15 | $-0.17 | -13.3% | ✗ MISS |
Q1 2020 | Feb 14, 2020 | $-0.05 | $0.03 | +160.0% | ✓ BEAT |
Latest News
Loading news...
Frequently Asked Questions about IMGN
What is IMGN's current stock price?
ImmunoGen, Inc. (IMGN) is currently trading at $31.23 per share. The stock has moved +0.02% today.
What is the analyst price target for IMGN?
The average analyst price target for IMGN is $12.72, based on 1 analyst.
What sector is ImmunoGen, Inc. in?
ImmunoGen, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is IMGN's market cap?
ImmunoGen, Inc. has a market capitalization of $8.73 billion, making it a mid-cap company.
Does IMGN pay dividends?
No, ImmunoGen, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALPN
Alpine Immune Sciences, Inc.
$64.97
Mkt Cap: $4.5B
BPMC
Blueprint Medicines Corporation
$129.46
Mkt Cap: $8.4B
CERE
Cerevel Therapeutics Holdings, Inc.
$44.96
Mkt Cap: $8.2B
ISEE
IVERIC bio, Inc.
$39.95
Mkt Cap: $5.5B
KRTX
Karuna Therapeutics, Inc.
$329.83
Mkt Cap: $12.6B
OSH
Oak Street Health, Inc.
$39.00
Mkt Cap: $9.5B
RETA
Reata Pharmaceuticals, Inc.
$172.36
Mkt Cap: $6.6B
ROIV
Roivant Sciences Ltd.
$22.41
Mkt Cap: $15.6B
RXDX
Prometheus Biosciences, Inc.
$199.92
Mkt Cap: $9.6B
SGFY
Signify Health, Inc.
$30.49
Mkt Cap: $8.9B
Explore stocks similar to IMGN for comparison